SEOM‑GEINO clinical guidelines for grade 2 gliomas (2023)
-
María Ángeles Vaz Salgado [1] ; Belén Cigarral García [2] ; Isaura Fernández Pérez [5] ; Beatriz Jiménez Munárriz [6] ; Ainhoa Hernández González [7] ; Paula Sampedro Domarco [3] ; María Vieito Villar [8] ; María Luisa Villamayor Delgado [1] ; Juan Manuel Sepúlveda Sánchez [9] ; Raquel Luque Caro [4]
-
[1] Hospital Ramón y Cajal
Hospital Ramón y Cajal
Madrid, España
-
[2] Hospital Universitario de Salamanca
Hospital Universitario de Salamanca
Salamanca, España
-
[3] Complexo Hospitalario Universitario de Ourense
Complexo Hospitalario Universitario de Ourense
Ourense, España
-
[4] Hospital Universitario Virgen de las Nieves
Hospital Universitario Virgen de las Nieves
Granada, España
-
[5] Medical Oncology Department, Hospital Alvaro Cunqueiro-Complejo Hospitalario Universitario de Vigo, Pontevedra, Spain
-
[6] Medical Oncology Department, HM Universitario Sanchinarro-CIOCC, Madrid, Spain
-
[7] Medical Oncology Department, Hospital Germans Trias I Pujol(ICO)-Badalona, Instituto Catalán de Oncología, Barcelona, Spain
-
[8] Medical Oncology Department, Hospital Universitario Vall D’Hebron, Barcelona, Spain
-
[9] Neuro-Oncology Unit, HM Universitario Sanchinarro-CIOCC, Madrid, Spain
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 11, 2024, págs. 2856-2865
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
The 2021 World Health Organization (WHO) classifcation has updated the defnition of grade 2 gliomas and the presence of isocitrate dehydrogenase (IDH) mutation has been deemed the cornerstone of diagnosis. Though slow-growing and having a low proliferative index, grade 2 gliomas are incurable by surgery and complementary treatments are vital to improving prognosis. This guideline provides recommendations on the multidisciplinary treatment of grade 2 astrocytomas and oligodendrogliomas based on the best evidence available.
